A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.